drugset

drugset / Trial / NCT06113445

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445 ↗

Phase 3 Active not recruiting 467 enrolled Incyte Corporation

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Timeline

Start: 2023-11-29
Primary completion: 2026-02-24
Completion: 2027-02-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Povorcitinib	Small molecule	—	Oral

Indications